3 Reasons Why Growth Investors Shouldn't Overlook Vertex (VERX)
Vertex (VERX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex enjoys a monopoly that could soon grow stronger. The company could have multiple potential blockbuster drugs on the way.
Vertex, Inc.: Growth Momentum Continues With FCF Conversion Rates Inflecting Upwards
Bullish on Vertex, Inc. due to strong growth outlook. 2Q24 results show solid growth across the board, with a strong FCF conversion rate. Ecosio acquisition is accretive, improving product offering, and expected to drive growth in the future.
Is Vertex (VERX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
Vertex, Inc. (VERX) Q2 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q2 2024 Results Conference Call August 7, 2024 8:30 AM ET Company Participants Joe Crivelli - VP, IR David DeStefano - President and CEO John Schwab - CFO Conference Call Participants Brad Reback - Stifel Joshua Reilly - Needham Rob Oliver - Baird Chris Quinter - Morgan Stanley Steve Enders - Citi Daniel Jester - BMO Capital Markets Adam Hotchkiss - Goldman Sachs Alex Sklar - Raymond James Patrick Walravens - Citizens JMP Securities Jake Roberge - William Blair Operator Good morning. And welcome to the Vertex Inc. Second Quarter 2024 Earnings Conference Call.
Vertex (VERX) Tops Q2 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis treatment, Vanzacaftor Triple, and the non-opioid pain management drug Suzetrigine, both with PDUFA dates expected in January 2025. Positioning the company for substantial future growth. The potential approvals of Vanza Triple will reinforce the Company's leadership in CF, while Suzetrigine's and the NOPAIN Act in 2025 will facilitate its entry into the lucrative pain management market.
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.
